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P450 monooxygenase ComJ catalyses side chain
phenolic cross-coupling during complestatin
biosynthesis†
Aurelio Mollo, ‡a A. Nikolai von Krusenstiern,‡a Joshua A. Bulos,a Veronika Ulrich,b
Karin S. A˚kerfeldt, a Max J. Cryle *bcd and Louise K. Charkoudian *a
Complestatin is a non-ribosomal heptapeptide belonging to the glycopeptide antibiotic family that displays
anti-complement, anti-HIV integrase, neuroprotective, anti-apoptotic, and antibacterial activities.
Development of complestatin as a pharmaceutical agent and biological probe has been stymied by the
difficulty in isolating the molecule from its natural source, Streptomyces lavendulae, as well as by the
uneconomical and environmentally unfriendly nature of current total synthetic routes. Of particular
challenge to the organic chemist is the installation of the biaryl and aryl–ether–aryl linkages that provide
complestatin with the structural rigidity responsible for its potent pharmacological properties. Herein, we
demonstrate that ComJ, a P450 monooxygenase from the complestatin biosynthetic gene cluster, can
catalyse phenolic cross-linking of amino acid side chains in vitro. ComJ acts with high efficiency and low
substrate stereoselectivity, a finding which paves the way towards the use of ComJ as a biocatalyst for
the chemo-enzymatic synthesis of complestatin and other related molecules. The ability of ComJ to
accept peptides of alternative stereochemistries raises intriguing questions about the evolutionary origins
of glycopeptide antibiotic biosynthesis and the capacity of S. lavendulae to produce different
conformations of complestatin.
1. Introduction
Glycopeptide antibiotics (GPAs) are an important class of non-
ribosomal peptides (NRPs) used to treat Gram-positive bacte-
rial infections.1 They are assembled independently of the ribo-
some by large enzyme complexes known as non-ribosomal
peptide synthetases (NRPSs). NRPs are typically assembled in
an N-to-C fashion, with each amino acid incorporated by its own
distinct module comprised of multiple catalytic domains
(Fig. 1). The “core” domains include: (1) the adenylation (A)
domain, responsible for selecting the correct amino acid for
incorporation and activating it as a mixed anhydride in an ATP-
dependent reaction; (2) the peptidyl carrier protein (PCP)
domain, responsible for nucleophilic attack of the A domain-
activated amino acid via its post-translationally-introduced
phosphopantetheine (Ppant) arm, resulting in thioester-
ication of the amino acid and freeing the A domain to activate
another amino acid; and (3) the condensation (C) domain,
responsible for catalysing peptide bond formation between the
newly formed aminoacyl-PCP and an upstream peptidyl-PCP,
thus increasing the length of the peptide chain by one amino
acid.
Among NRPs, GPAs are unique in that they are characterised
by a high percentage of non-proteinogenic amino acids as well
as synthetically challenging biaryl and biaryl ether linkages.1,2
These unusual cross-links, absent from traditional ribosome-
assembled peptides, play important roles in rigidifying the
peptide scaffold into potent bioactive conformations. In vivo,
the biaryl and biaryl ether linkages are installed stereo- and
regioselectively by dedicated P450 monooxygenases (known as
“Oxy enzymes”),3 which are recruited to the terminal module of
the NRPS by the adjacent X-domain, a conserved domain
present in the terminal module of all GPA NRPSs.4 Recent
results indicate that the Oxy enzymes undergo a continuous
association/dissociation process with the X-domain, only to
“lock in” upon recognition of their cognate substrate and thus
catalysing side chain cross-linking in a dened order.5 Due to
their potential use as biocatalysts, Oxy enzymes from many
different GPA systems have been structurally and biochemically
characterised to date.6–11 In the future, these enzymes could
prove to be useful tools for enabling access to novel structural
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and chemical diversity, including molecules that contain biaryl
motifs that would otherwise be challenging to synthesise via
classical approaches.12
Complestatin (Fig. 1) is an atypical GPA isolated in the early
1980s from the soil bacterium Streptomyces lavendulae.13 It
possesses a remarkable range of pharmacological properties,
including anti-complement,13 anti-HIV integrase,14,15 neuro-
protective,16,17 anti-apoptotic,18 and antibacterial19 effects.
Because of the presence of an aryl–ether–aryl–aryl moiety cross-
linking three of its amino acid side chains, total synthetic
approaches towards complestatin remain arduous. Current
routes in fact require in excess of 20 steps and involve the use of
large amounts of metal catalysts, together rendering these
routes economically and environmentally unsustainable for
industrial scale productions.2,20–22 A greener, more efficient
route towards the synthesis of this molecule and its analogues,
which may be used as biological probes or as lead compounds
in drug development, is greatly needed.
Complestatin's regulatory and biosynthetic gene cluster
(BGC) was rst sequenced and annotated in 2001. At the time
it was inferred based on homology that two enzymes, called
ComI and ComJ, are involved in cyclising the linear hepta-
peptide to yield fully active complestatin (Fig. 1).23 More
recently, it was shown through gene disruption studies and
subsequent analysis of cell extracts that ComI and ComJ are
indeed responsible for installing the biaryl and phenolic
bridges, respectively, with ComJ acting prior to ComI.24 In
spite of these advances, however, ComI and ComJ have not
been shown to be active in vitro, a result critical to further
developing these enzymes into useful biocatalysts. Previous
work in the eld has suggested that an environmentally
friendly route might involve the synthesis of the linear form of
complestatin, followed by P450-mediated cross-linking,4,25
thus exploiting the remarkable biosynthetic capability of P450
enzymes to install the synthetically-challenging crosslinks.
Towards this goal, we herein demonstrate that ComJ is an
active P450 enzyme that catalyses aryl–ether–aryl bond
formation in vitro with high efficiency and low substrate ster-
eoselectivity, dening it as a potential biocatalyst for the
chemo-enzymatic reconstitution of complestatin and related
molecules.
2. Materials and methods
2.1 Chemicals and reagents
All chemicals were purchased from commercial vendors and
used without further purication. Solvents used for solid-phase
peptide synthesis (SPPS) were purchased as anhydrous
reagents. All resins used were purchased from CreoSalus
(Advanced ChemTech). Enzymes for molecular cloning work
were obtained from New England BioLabs. NMR spectra were
recorded on a Varian (Agilent) 500 MHz NMR Spectrometer.
Fig. 1 The complestatin NRPS is composed of 29 distinct domains distributed across four proteins (ComA–D). The domains are arranged into
seven functional modules (M1–M7), each responsible for the incorporation of one amino acid into the growing chain; putative intermediates
found at each module are shown tethered to their cognate carrier protein domains. When the growing chain reaches the terminal module as an
a-ketoacyl hexapeptide, it is chlorinated by in trans-acting halogenases (not shown),35 then cyclised by the in trans-acting P450s ComI and
ComJ to yield fully active complestatin (boxed). Bioinformatic analysis suggests that M6 contains an additional E domain (dashed) that was
overlooked in the original annotation (see text):32 the structure of complestatin is shown as published, but the stereochemistry of the tyrosine
residue remains unclear. A ¼ adenylation domain; PCP¼ peptidyl carrier protein domain; C ¼ condensation domain; E ¼ epimerisation domain;
Mt ¼ N-methyltransferase domain; L ¼ extended linker domain; TE ¼ thioesterase domain; M ¼ module.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35376–35384 | 35377
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Turnover mixtures were analysed using an Agilent 6545 Q-TOF
LC/MS.
2.2 Cloning
Expression plasmids for ComI, ComJ, ComK (pET28a) and the
complestatin NRPS-specic PCP7-Xcom protein (pET24b)26 were
constructed via Gibson Assembly using template DNA from S.
lavendulae. PCP7com and Xcom were cloned from a synthetic
gene optimised for E. coli expression (Eurons MWG, Ebers-
berg, Germany) using specic primers; PCP7com and Xcom were
then cloned into a modied MBP-containing pET24b vector26
using restriction digestion (NcoI/XhoI) and subsequent ligation
as described previously.4,27 See ESI for details.†
2.3 Protein expression and purication
All proteins used in this paper were designed to exhibit an N-
terminal His6-tag and expressed in BL21(DE3) competent cells.
Cultures were grown in LB medium§ at 37 C, 225 RPM, to an
OD of 0.6–0.8 before protein production was induced with
0.25 mM IPTG; the cultures were subsequently incubated
overnight (12–16 h) at 18 C, 100 RPM. In the case of the P450
enzymes (ComI, ComJ), the production culture was supple-
mented with d-aminolevulinic acid (0.5 mM) to promote
formation of the heme moiety, while for ferredoxins (SpFd,
ComK) the culture was supplemented with 50 mM FeSO4 to
facilitate the assembly of the [2Fe–2S] cluster. Following har-
vesting of the production cultures (14 300  g, 8 min, 4 C), the
cells were resuspended in lysis buffer (50 mM phosphate pH
7.6, 300 mM NaCl, 10 mM imidazole) and lysed by sonication
(8  15 s pulses with 30 s rest in between, employing a Misonix
Microson XL-2000 Ultrasonic Liquid Processor, Power Setting:
7). The lysates were centrifuged (25 000  g, 50 min, 4 C) and
the supernatant incubated with 2–3 mL of pre-equilibrated Ni-
NTA resin (GoldBio) for 2–3 h, then transferred to a large
Econo-Pac® column (Bio-Rad). The resin was washed twice
(50 mM phosphate pH 7.6, 300 mM NaCl, 30 mM imidazole)
and the protein subsequently eluted (50 mM phosphate pH
7.6, 300 mM NaCl, 300 mM imidazole). The identity and purity
of the proteins were conrmed by SDS-PAGE (Fig. S1†) and the
concentrations measured via sequence-based 280 nm extinc-
tion coefficients. Aer dialysis (Slide-A-Lyzer™ Dialysis
Cassette, Thermo Fisher Scientic) into storage buffer (50 mM
phosphate pH 7.6, 10% glycerol), all proteins were aliquoted,
ash-frozen in liquid N2, and stored at 80 C (see Fig. S1†
for titers).
In preparation for spectral assays, ComI and ComJ were
further puried in a two-step process consisting of anion
exchange chromatography (AEC) and size-exclusion chroma-
tography (SEC). Initially, the proteins were buffer exchanged
with AEC buffer A (50 mM Tris–HCl pH 7.4, 20 mM NaCl) using
Illustra NAP-25 columns (GE Healthcare, Chalfont St Giles, UK)
and then concentrated using Vivaspin® centrifugal concentra-
tors (30 000 MWCO; Sartorius, Go¨ttingen, Germany). AEC was
performed using a 6 mL Resource™ Q column (GE 17–1179)
equilibrated with AEC buffer A and connected to an A¨kta puri-
er 10 system (GE) at RT. The protein was applied onto the
column, which was then washed with 5 column volumes (CV) of
AEC buffer A, before the protein was eluted over a gradient from
0 to 100% AEC buffer B (50 mM Tris–HCl pH 7.4, 1 M NaCl) over
20 CV. The elution fractions were analysed by SDS-PAGE, with
relevant fractions pooled and concentrated prior to SEC. For
SEC, protein was loaded onto a Superose 12 300 mL column (GE
17-5173) equilibrated using SEC buffer (50 mM Tris–HCl pH 7.4,
150 mM NaCl) and connected to an A¨kta purier 10 system at
RT. The protein was eluted using 50 mM Tris–HCl pH 7.4,
150 mM NaCl, and analysed by SDS-PAGE. Relevant fractions
were pooled, and the protein portioned into aliquots prior to
being ash-frozen in liquid N2 and stored at 80 C.
2.4 Spectral assays
Spectral analysis of ComI and ComJ was performed using a V-
650 UV-vis spectrophotometer (JASCO Germany GmbH; Groß-
Umstadt, Germany) and the SpectraManager™ soware. Data
was recorded (1 cm pathlength) using 2.5 mM cytochrome P450
in 50 mM Tris–HCl buffer pH 8.0 at 30 C from l ¼ 390–600 nm
in 0.2 nm increments for the ferric protein (as puried) as well
as for the protein that had been reduced and saturated with
carbon monoxide (ferrous-CO). The protein was reduced
through the addition of 10 mL of a saturated Na2S2O4 solution.
Directly aer protein reduction, saturation with carbon
monoxide was achieved through bubbling of 60 mL of carbon
monoxide gas through the cuvette lled with protein solution
via a syringe.
2.5 Analytical size-exclusion chromatography
Experiments were performed with 33.3 mM of cytochrome P450
incubated with 100 mM of the NRPS construct of interest in SEC
buffer (50 mM Tris–HCl pH 7.4, 150 mM NaCl) in a volume of
100 mL at RT for 30 min. This reaction mixture was analysed by
SEC using SEC buffer and a ow rate set at 1 mL min1 and
a Superose 12 10/300 GL column (GE 17-5173) connected to an
A¨kta purier 10 system controlled by UNICORN 5.20 AB so-
ware (GE Healthcare, Chalfont St Giles, UK). Data were analysed
using GraphPad Prism 6. For all cases, individual proteins were
analyzed as controls.
2.6 Solid-phase peptide synthesis
The target tripeptides (Ac-NH-D-Hpg-D-Hpg-L-Tyr-OH ¼ 1, Ac-
NH-D-Hpg-D-Hpg-D-Tyr-OH ¼ 2) were constructed on Wang
Resin on a 0.2 mmol scale using the Fmoc/tBu-based SPPS
approach developed in previous work.28 The starting material
for 1 was L-Tyr-loadedWang resin, whereas the starting material
for 2 was “free”Wang resin.{ For the synthesis of 2, Wang resin
was loaded overnight at ambient temperature using 2.5 eq. of
amino acid (Fmoc-NH-D-Tyr(tBu)-OH) in the presence of 5 eq. of
§ It was observed that expressing ferredoxins in TB medium resulted in higher
yields compared to expressing the same proteins in LB medium.
{ The decision to start from freeWang resin instead of D-Tyr-loadedWang resin in
the synthesis of 2 was based on the much lower purchase price of free Wang resin
compared to the corresponding pre-loaded resin.
35378 | RSC Adv., 2017, 7, 35376–35384 This journal is © The Royal Society of Chemistry 2017
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the coupling agent N,N0-diisopropylcarbodiimide (DIC), 0.1 eq.
of the catalytic base 4-dimethylaminopyridine (DMAP), 2.5 eq.
of the racemisation inhibitor hydroxybenzotriazole (HOBt), all
in 9 : 1 N,N-dimethylformamide (DMF): dichloromethane
(DCM). Subsequent amide coupling reactions were performed
over 40 min at ambient temperature in 8 mL of a 0.1 M trie-
thylamine (TEA) solution in DMF containing 4 eq. of amino
acid, 4 eq. of DIC, and 8 eq. of HOBt. Deprotection reactions of
the Fmoc protecting group were performed over 2 min with 8
mL of 1% v/v 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in DMF.
Finally, to prevent homodimerisation of the peptide during
subsequent thioesterication, the reactive N-terminus of the
resin-bound, Fmoc-deprotected tripeptide was “capped” with
an acetyl group through the addition of 1.1 eq. of acetic anhy-
dride in 8 mL DMF for 1 min. The tripeptide was cleaved from
the resin via a 2.5 h incubation with 9 mL triuoroacetic acid,
0.5 mL thioanisole, 0.3 mL 1,2-ethanedithiol, 0.2 mL anisole,
and analysed by NMR spectroscopy (see Fig. S7 and S8†).
2.7 Priming the peptide for PCP loading
In order to prepare the peptide for loading onto PCP7-Xcom,
the peptide was rst converted to a thiophenol thioester by
reacting the cleaved peptide (20 mg) for 40 min with 5 eq. of
thiophenol in the presence of 1.2 eq. of (benzotriazol-1-yl-oxy)
tripyrrolidinophosphonium hexauorophosphate (PyBOP)
and 1.2 eq. of N,N-diisopropylethylamine (DIPEA) in 1 mL DMF.
Following isolation of the thiophenol conjugate via acetonitrile
(ACN) precipitation and centrifugation (see Fig. S9 and S10†
for NMR data), the compound (10 mg) was transthioesteried
with coenzyme A (CoA, trilithium salt, Sigma Aldrich) via a 2–3 h
incubation with 0.875 eq. of CoA in 4 mL of a 2 : 1 H2O : ACN
mixture (50 mM phosphate pH 8.30), and the product
puried via solid phase extraction (Strata-X polymeric reversed
phase; Phenomenex, Torrance, CA) as detailed elsewhere29
(for NMR data, see Fig. S11 and S12;† for MALDI data, see
Fig. S13 and S14†).
2.8 Turnover assays
A PCP stock solution was dialysed overnight at 4 C against 1 L
reaction buffer (50 mM NaCl, 50 mM HEPES, pH 7.00). Each
loading reaction (350 mL) consisted of the following: 60 mMPCP,
240 mM peptidyl-CoA, 50 mM MgCl2 and 6 mM Sfp R4-4 in
reaction buffer. The loading reactions were incubated for 1 h at
30 C with gentle shaking (150 RPM), aer which they were
transferred to pre-equilibrated centrifugal lters (30 000
MWCO, Vivaspin® by Sartorius) and the excess of peptidyl-CoA
was removed by a concentration dilution (4  1 : 5 dilution)
procedure using reaction buffer. The buffer-exchanged peptidyl-
PCP was used to set up turnover reactions (210 mL) consisting of:
50 mM peptidyl-PCP, 8 mM Oxy (OxyBvan/ComJ), 10 mM E. coli
avodoxin reductase, 20 mM ferredoxin (SpFd/ComK), 2 mM
glucose-6-phosphate, 1 U glucose-6-phosphate dehydrogenase,
2 mM NADPH, all in reaction buffer. The turnover mixtures
were incubated for 1 h at 30 C, 300 RPM, with the caps le open
to provide O2 as a reactant. The contents of each reaction tube
were then separated into 2  105 mL portions, to each of which
15 mL of 40% v/v MeNH2/H2O were added (23 000 molar
excesses over peptide), followed by a further incubation of
15 min at 30 C, 300 RPM. Each 120 mL mixture was diluted to
500 mL with H2O, then to 1 mL with 1 : 50 formic acid
(FA) : H2O. The mixture was added to an SPE column that had
been pre-activated with 1 mLMeOH and pre-equilibrated with 1
mL H2O. The columns were washed with 1 mL 5% MeOH/H2O
and the turnover species nally eluted with 500 mL 1% FA/
MeOH. The combined elutes were concentrated down to 100
mL using a SpeedVac concentrator and analysed by LC/MS with
detection in negative mode and simultaneous measurement of
205 nm absorbance (see ESI for details†). The UV and extracted
ion count (EIC) data was exported into Prism 7 for visualisation
and analysis. The extent of conversion of linear peptide into
cyclised product was estimated by quantifying the per cent
decrease in 205 nm absorbance of the reactant starting mate-
rial. All experiments were carried out in triplicate and the
difference in means determined by the t-test (parametric and
unpaired, no Welch's correction).
3. Results and discussion
3.1 Spectral assays
In order to investigate the potential catalytic competence of
ComI and ComJ, a spectral assay was initially performed. The
UV-visible spectra of the two proteins presented the following
features: a Soret maximum at lmax ¼ 418 nm and b/a bands at
lmax ¼ 537 and 572 nm in the case of ComJ; and a Soret
maximum at lmax ¼ 418 nm and b/a bands at lmax ¼ 535 and
570 nm in the case of ComI (Fig. 2). These spectra correspond to
the characteristic absorption spectra of cytochrome P450
enzymes in the low-spin resting state, with the heme iron in its
water-bound ferric form.30 Reduction of the proteins using
Na2S2O4 resulted in the reduction of ferric to ferrous heme;
subsequent saturation of the protein solution with carbon
monoxide (CO) led to the displacement of the water ligand by
CO and signicant changes in the UV-vis absorption spectra
(Fig. 2). In particular, the appearance of a major peak at
approximately lmax ¼ 450 nm in the spectrum of each protein
suggested that the axial cysteine ligand was present mostly in its
deprotonated thiolate state, indicating that ComI and ComJ
were catalytically competent cytochrome P450s.
Fig. 2 Spectral analyses of (A) ComJ and (B) ComI. The absorption
spectra were recorded for ferric (magenta) and ferrous-CO (blue)
hemes from 390–600 nm. The appearance of a 450 nm peak in the
ferrous-CO spectrum of both proteins suggests they are catalytically
competent cytochrome P450s.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35376–35384 | 35379
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We next evaluated whether ComI and ComJ interact with
PCP domains, X-domains, and/or PCP-X didomains from the 7th
module of the complestatin NRPS, thus opening up the possi-
bility of a biomimetic route to synthesis of the molecule.
Monomeric Xcom (X-domain from M7 of complestatin NRPS;
see Fig. 1), PCP7com (PCP domain from M7 of complestatin
NRPS; see Fig. 1), and heterodimeric PCP7-Xcom constructs were
designed and cloned into modied pET vectors, containing
maltose-binding protein (MBP) to enhance solubility and
expression titers, as detailed in Section 2.2.
Protein–protein interactions were next evaluated by analyt-
ical size-exclusion chromatography (SEC) with simultaneous
monitoring of the absorption at l ¼ 280 nm for protein
absorption and at l ¼ 415 nm for the heme-specic (P450)
absorption. The results (Fig. 3) indicate that ComI and ComJ
both interact tightly with MBP-PCP7-Xcom. In addition to the
above-mentioned interaction, both P450s exhibited tight inter-
action with monomeric Xcom constructs (Fig. S2†) but not with
monomeric PCP7com constructs (Fig. S3†). Collectively, these
data suggest that interaction of ComI and ComJ with the NRPS
assembly line in vivo occurs primarily through the X-domain.5
Having established the ability of the catalytically competent
P450s to dock onto the PCP7-Xcom didomain, we proceeded to
testing the ability of ComJ to catalyse a cyclisation reaction
(Fig. 4). Previous research by the Robinson Lab found that
OxyBvan, the ComJ homologue from the vancomycin biosyn-
thetic pathway, was able to successfully cyclise a tripeptide
substrate in vitro representing the core of the cognate hepta-
peptide.31 Based on this precedent, we investigated the ability of
ComJ to cyclise a tripeptide substrate representing the core of
the complestatin heptapeptide (Fig. 4).
In addition to testing the cyclisation efficiency of D-Hpg-D-
Hpg-L-Tyr (1)—the tripeptide substrate based on the published
structure of complestatin—we also evaluated the epimeric tri-
peptide D-Hpg-D-Hpg-D-Tyr (2). The rationale behind this was
two-fold. First, a recent bioinformatics analysis of the comple-
statin BGC revealed the presence of an additional, predicted
epimerisation domain in module 6 of the complestatin NRPS
that was not reported in the original annotation32 (Fig. 1), which
suggests possible enzymatic conversion of the L-Tyr residue to D-
Tyr during biosynthesis. Second, alternative conformations of
complestatin and the existence of structurally related natural
products from Streptomyces isolates have been reported in the
literature.2 Together, these ndings inspired us to explore the
stereoselectivity of ComJ.
The target peptides were constructed using Fmoc/tBu-based
SPPS on the Wang resin. Due to the high susceptibility of Hpg
residues to racemisation during peptide synthesis, the Fmoc-
deprotection and coupling protocols were optimised to mini-
mise the length and intensity of exposure of the peptides to
basic conditions (see Section 2.6).28 The peptides were cleaved
from the resin, then converted to their CoA conjugates via
a thiophenol intermediate before being loaded onto the PCP7-
Xcom didomain in an Sfp-dependent reaction.33 Aer incubating
peptidyl-PCP with the relevant cytochrome P450 enzyme for 1 h
at 30 C, turnover was evaluated via methylamine-assisted
cleavage, followed by solid-phase extraction (SPE) and LC-
QTOF-MS detection (Fig. 4).
The robustness of the coupled turnover and LC-MS detection
protocol was tested by performing a positive control for turn-
over based on the results of Robinson and co-workers. Thus, the
L-Tyr-containing tripeptide (1) was loaded onto MBP-PCP7-
Xvan25 and OxyBvan added as the P450. This resulted in 79%
turnover (Fig. S4†) in agreement with published results.31
Next, the biocatalytic activity of ComJ was tested by per-
forming turnover of 1 loaded onto MBP-PCP7-Xcom. As shown in
Fig. 5, 1 was turned over by ComJ in 48% efficiency, with
spinach ferredoxin (SpFd) providing the reducing equivalents to
ComJ. This constitutes the rst direct observation of ComJ
activity in vitro. In addition to turning over 1, ComJ was also
found to turn over the D-Tyr-containing tripeptide 2 with
a slightly higher efficiency of 60% (P < 0.001, Fig. 5E), suggesting
that ComJ may possess a slight preference for D- over L-Tyr. The
nding that ComJ can accept an epimerised peptide substrate
suggests that an alternative conformation of complestatin is in
fact a feasible product of the complestatin gene cluster.
We next tested the possibility of a tight ComJ-Xcom interac-
tion hindering catalysis, as we observed slightly lower extent of
conversion of the linear starting materials (1, 2) into cyclised
products (3, 4) by ComJ compared to the OxyBvan control (P <
0.0001 for both 1 and 2, Fig. 5E). It was recently discovered in
fact that the cytochrome P450 enzyme StaH involved in the
biosynthesis of the GPA A47934 possesses low catalytic effi-
ciency, and that when Xsta (X-domain from A47934 NRPS) is
Fig. 3 SEC traces for (A) ComJ and (B) ComI, alone (left) and in the presence of MBP-PCP7-Xcom (right). Absorptions at l ¼ 280 nm (blue;
protein-specific) and at l ¼ 415 nm (magenta; heme-specific) were monitored simultaneously. A shift towards smaller retention volumes is
evident upon addition of MBP-PCP7-Xcom to either P450, indicative of complexation. [P450] 33.3 mM, [PCP-X] 100 mM.
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exchanged with Xtei (X-domain from teicoplanin NRPS), the
P450 activity increases dramatically, which suggests that an
overly tight interaction between StaH and Xsta hinders catalytic
efficiency in vitro.27 However, in our case, exchanging MBP-
PCP7-Xcom with MBP-PCP7-Xvan did not result in any signicant
increase in turnover (Fig. S5†), allowing us to exclude this
hypothesis in this particular case.k Increasing the reaction time
for turnover also did not result in more cyclised product
(Fig. S5†).
The fully annotated complestatin BGC (GenBank:
AF386507.1) encompasses comK, whose protein product was
predicted based on homology to be a ferredoxin.23 Thus, we
decided to test the relative efficiency of ComK versus SpFd in
transferring reducing equivalents to ComJ. Expressing ComK
in TB medium supplemented with 50 mM FeSO4 (see Section
2.2) resulted in brown protein fractions, consistent with the
presence of a chromophoric [2Fe–2S] cluster absorbing at
422 nm (Fig. S6†).34 As shown in Fig. 5, replacing SpFd with
ComK resulted in 20% turnover for both L- and D-Tyr-
containing tripeptides, with the turnover rate for the latter
being slightly higher (P < 0.05, Fig. 5E). This represents the
rst observation of ComK acting as a ferredoxin, although
spinach ferredoxin remains superior with respect to turnover
efficiency. One hypothesis suggested by Khosla and co-
workers23 is that in vivo, ComK is likely to interact with
a specic electron source encoded outside the complestatin
BGC. We speculate that the characterisation and subsequent
inclusion of this oxidoreductase in the turnover mixture might
enable higher rates of turnover, comparable if not superior to
those achieved with spinach ferredoxin.
Turnover was also attempted using longer, non-chlorinated
heptapeptides, but no turnover could be detected (data not
shown). Recent results suggest that chlorine atoms may play
a role in helping orient peptide substrates in the polar P450
active site,35 and therefore it is possible that the non-
chlorinated heptapeptides were simply too non-polar to
interact favourably with the P450 enzyme. With that in mind,
future studies should investigate the activity on substrates
that more closely resemble the natural substrates for
cyclisation.
Fig. 4 Summary of the reaction flow from starting linear peptide to cyclised product. (A) Complestatin is a bismacrocyclic heptapeptide. Each
ring is installed by a separate P450 enzyme (see Fig. 1). Inspired by the left-hand macrocycle, containing a biaryl ether bond (boxed), we
constructed epimeric linear tripeptides (1, 2) by solid-phase peptide synthesis (SPPS). Following cleavage from the resin, the peptides (R ¼ OH)
were converted to CoA conjugates (R¼ SCoA) via a thiophenol intermediate (R¼ SPh), before being loaded onto an MBP fusion construct of the
PCP7-X didomain from the complestatin NRPS (R ¼ S-Ppant-PCP7-Xcom; Ppant structure shown in part B). (B) Peptidyl-PCP, shown top, was
treated with ComJ and other proteins required to provide a sustained electron flow to the P450 heme. Following biaryl ether bond installation
over a 1 h period, the cyclised product was cleaved using methylamine, purified by solid-phase extraction (SPE), and detected by LC-MS. See
Section 2.7 for complete procedure.
k Although PCP7van was exchanged for PCP7com, effects from direct PCP-Oxy
binding can be excluded given that ComJ does not appear to bind to the PCP7
domain but only to the X-domain (Fig. S2 and S3†).
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 35376–35384 | 35381
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4. Conclusions
In conclusion, we report the rst direct observation of in vitro
activity by ComJ, the biaryl ether-installing P450 from the
complestatin BGC. ComJ turned over the model tripeptide 1 in
48% yield and 2 in 60% yield, revealing a lack of strong
substrate stereoselectivity. The slight preference for 2 (D-Tyr-
containing peptide) over 1 (L-Tyr-containing peptide) fuels the
question as to whether the complestatin NRPS can make and
process a peptide containing a D-Tyr-residue at position 6.
Future experiments will be needed to determine the role of the
epimerisation domain in module 6 and the capacity of the
complestatin gene cluster to biosynthesise an alternative
conformation of complestatin.
The experiments presented here focused on ComJ as a biaryl
ether-installing P450, but the UV/vis and SEC data reveal that
ComI also possesses all the characteristics of a competent P450
that is able to interact productively with the NRPS machinery.
Future studies will need to investigate ComI activity—especially
in conjunction with prior cyclisation by ComJ—thus completing
the picture of complestatin biosynthesis and paving the way
towards a chemo-enzymatic synthesis of the molecule and
potential derivatives.
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Fig. 5 Results of turnover studies on 1 (D-Hpg-D-Hpg-L-Tyr) and 2 (D-Hpg-D-Hpg-D-Tyr). (A) Schematic showing turnover of PCP-X—bound
tripeptide by ComJ. The linear form of the peptide (post-methylamine cleavage) has anm/z of 533.2 (negative mode), whereas the cyclised form
has anm/z of 531.2, 2 Da lower owing to the loss of two hydrogen atoms. (B) Left: UV trace showing the decrease in linear peptide concentration
in the presence of ComJ and either ComK (red dotted line) or SpFd (green dashed line) for 1 loaded on MBP-PCP7-Xcom. Right: extracted ion
count (EIC) showing the concomitant increase in cyclised product. (C) Left: UV trace showing the decrease in linear peptide concentration in the
presence of ComJ and either ComK (blue dotted line) or SpFd (orange dashed line) for 2 loaded on MBP-PCP7-Xcom. Right: EIC showing the
concomitant increase in cyclised product. In both B and C, solid black lines represent negative (no ComJ) controls. (D) Mass spectra for linear
peptide (left, m/z ¼ 533.203, expected: 533.204) and cyclised product (right, m/z ¼ 531.187, expected: 531.188). (E) Bar graph summarising the
turnover percentages of 1 and 2 by ComJ in the presence of SpFd or ComK; the presenting PCP construct for all ComJ reactions was MBP-
PCP7-Xcom. The positive control with OxyBvan as the P450 and MBP-PCP7-Xvan as the peptide presentation platform is shown for comparison
(see Fig. S4† for relevant spectra). All experiments were performed in triplicate and turnover percentages computed by quantifying the decrease
in linear starting material concentration relative to the negative (no Oxy) controls. Significant differences between means were computed using
the unpaired t-test. *P < 0.05, ***P < 0.001, ****P < 0.0001.
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Abbreviations
A Adenylation domain
ACN Acetonitrile
AEC Anion exchange chromatography
BGC Biosynthetic gene cluster
C Condensation domain
CoA Coenzyme A
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM Dichloromethane
DIC N,N0-Diisopropylcarbodiimide
DIPEA N,N-Diisopropylethylamine
DMAP 4-Dimethylaminopyridine
DMF N,N-Dimethylformamide
E Epimerisation domain
EcoFlvR E. coli avodoxin reductase
EIC Extracted ion count
FA Formic acid
GPA Glycopeptide antibiotic
G6P Glucose-6-phosphate
G6P-DH Glucose-6-phosphate dehydrogenase
HOBt Hydroxybenzotriazole
L Extended linker domain
M Module
MALDI Matrix-assisted laser desorption ionisation (mass
spectrometry)
MBP Maltose-binding protein
Mt N-Methyltransferase domain
NADPH Nicotinamide adenine dinucleotide phosphate
NRP Non-ribosomal peptide
NRPS Non-ribosomal peptide synthetase
PCP Peptidyl carrier protein domain
Ppant 40-Phosphopantetheine
PyBOP (Benzotriazol-1-yl-oxy)tripyrrolidinophosphonium
hexauorophosphate
Q-TOF LC/
MS
Quadrupole time-of-ight liquid chromatography/
mass spectrometry
SEC Size exclusion chromatography
SPE Solid-phase extraction
SpFd Spinach ferredoxin
SPPS Solid-phase peptide synthesis
tBu tert-Butyl (protecting group)
TE Thioesterase domain
TEA Triethylamine
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